Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 52-Week High - What's Next?

Amneal Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Amneal shares reached a 52-week high, touching $22.09 and trading about 4.6% higher than the prior close of $21.12.
  • Analyst sentiment is broadly positive: eight analysts rate the stock Buy and two Hold, giving it a Moderate Buy consensus and an average price target of $23.
  • The company reported quarterly earnings of $0.26 per share, beating the $0.23 consensus estimate; quarterly revenue was $862.68 million.
  • Five stocks we like better than Amneal Pharmaceuticals.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) shares hit a new 52-week high during mid-day trading on Wednesday. The stock traded as high as $22.09 and last traded at $22.0660, with a volume of 727,780 shares traded. The stock had previously closed at $21.12.

Analyst Upgrades and Downgrades

AMRX has been the subject of several recent research reports. Zacks Research raised shares of Amneal Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Monday, October 26th. UBS Group reissued a "buy" rating on shares of Amneal Pharmaceuticals in a research report on Thursday, October 1st. Barclays boosted their price target on shares of Amneal Pharmaceuticals from $16.00 to $20.00 and gave the stock an "overweight" rating in a research note on Thursday, September 17th. Piper Sandler reaffirmed an "overweight" rating and set a $21.00 price objective on shares of Amneal Pharmaceuticals in a research report on Wednesday, November 4th. Finally, Oppenheimer assumed coverage on Amneal Pharmaceuticals in a research note on Wednesday, September 23rd. They issued an "outperform" rating and a $27.00 price objective on the stock. Eight research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Amneal Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $23.00.

Check Out Our Latest Research Report on AMRX

Amneal Pharmaceuticals Stock Up 4.6%

The firm has a market cap of $7.70 billion, a PE ratio of 52.58, a PEG ratio of 2.42 and a beta of 1.24. The company has a current ratio of 1.87, a quick ratio of 1.24 and a debt-to-equity ratio of 5.61. The firm has a 50 day moving average price of $19.87 and a 200-day moving average price of $16.18.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.03. The firm had revenue of $862.68 million for the quarter. Amneal Pharmaceuticals had a net margin of 4.17% and a return on equity of 283.50%. Research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.98 EPS for the current fiscal year.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Large investors have recently modified their holdings of the company. Dimensional Fund Advisors LP boosted its holdings in shares of Amneal Pharmaceuticals by 1.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 5,690,586 shares of the company's stock valued at $70,723,000 after buying an additional 81,546 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of Amneal Pharmaceuticals by 16.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,831,581 shares of the company's stock valued at $76,900,000 after buying an additional 536,048 shares during the last quarter. Congress Asset Management Co. raised its stake in Amneal Pharmaceuticals by 94.7% during the 3rd quarter. Congress Asset Management Co. now owns 1,524,355 shares of the company's stock worth $30,701,000 after acquiring an additional 741,577 shares in the last quarter. Public Sector Pension Investment Board raised its stake in Amneal Pharmaceuticals by 73.4% during the 3rd quarter. Public Sector Pension Investment Board now owns 1,026,235 shares of the company's stock worth $20,032,000 after acquiring an additional 434,400 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in Amneal Pharmaceuticals during the 2nd quarter worth $17,573,000. 31.82% of the stock is owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Company Profile

(Get Free Report)

Amneal Pharmaceuticals is a U.S.-based pharmaceutical company that develops, manufactures and markets generic and specialty medicines. Its products include a broad range of generic drugs, including complex formulations and injectable medicines, as well as branded therapies in areas such as neurology and endocrinology. The company also operates AvKARE, which distributes pharmaceuticals and medical products to government, institutional and commercial customers. Amneal serves customers in the United States and in international markets.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Amneal Pharmaceuticals Right Now?

Before you consider Amneal Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amneal Pharmaceuticals wasn't on the list.

While Amneal Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines